NASDAQ:INFI - Infinity Pharmaceuticals Stock Price, Price Target & More

Get Started

$2.03 -0.02 (-0.98 %)

(As of 05/27/2018 06:13 AM ET)

Previous Close$2.03

Today's Range$1.99 - $2.06

52-Week Range$0.93 - $3.75

Volume288,858 shs

Average Volume380,172 shs

Market Capitalization$113.82 million

P/E RatioN/A

Dividend YieldN/A

Beta2.5

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for people with cancer in the United States. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program, including DUO study that is in randomized and monotherapy Phase III clinical study for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate; and AbbVie Inc. to develop and commercialize products containing duvelisib in oncology indications. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

SymbolNASDAQ:INFI

CUSIP45665G30

Webwww.infi.com

Phone617-453-1000

Debt

Debt-to-Equity RatioN/A

Current Ratio10.81

Quick Ratio10.81

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$6 million

Price / Sales18.97

Cash FlowN/A

Price / CashN/A

Book Value$0.81 per share

Price / Book2.51

Profitability

EPS (Most Recent Fiscal Year)($0.83)

Net Income$-41,830,000.00

Net MarginsN/A

Return on Equity-79.47%

Return on Assets-61.73%

Miscellaneous

Employees22

Outstanding Shares56,070,000

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) released its quarterly earnings data on Tuesday, May, 8th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.18) by $0.00. View Infinity Pharmaceuticals' Earnings History.

Who are some of Infinity Pharmaceuticals' key competitors?

Some companies that are related to Infinity Pharmaceuticals include GTX (GTXI), ProMetic Life Sciences (PFSCF), Innate Pharma (IPHYF), Sinovac Biotech (SVA), Clearside Biomedical (CLSD), Merus (MRUS), Synergy Pharmaceuticals (SGYP), Syros Pharmaceuticals (SYRS), American Brivision (Holding) (ABVC), Depomed (DEPO), MediciNova (MNOV), Albireo (ALBO), Tyme Technologies (TYME), Kala Pharmaceuticals (KALA) and Dermira (DERM).

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:

Ms. Adelene Q. Perkins, Chairman & CEO (Age 58)
Dr. Lawrence E. Bloch M.D., J.D., Pres, Principal Accounting Officer & Treasurer (Age 52)
Mr. Seth A. Tasker J.D., VP, Gen. Counsel & Sec. (Age 39)
Ms. Melissa Hackel, VP of Fin.
Dr. Jeffery L. Kutok M.D., Ph.D., Chief Scientific Officer & Sr. VP (Age 51)

Has Infinity Pharmaceuticals been receiving favorable news coverage?

Media stories about INFI stock have been trending somewhat positive recently, according to Accern Sentiment. The research group identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Infinity Pharmaceuticals earned a news impact score of 0.04 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 45.99 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

Who are Infinity Pharmaceuticals' major shareholders?

Infinity Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BIOTECHNOLOGY VALUE FUND L P (21.70%), Dimensional Fund Advisors LP (1.31%), Wasatch Advisors Inc. (0.64%), Millennium Management LLC (0.58%), GSA Capital Partners LLP (0.54%) and Wells Fargo & Company MN (0.35%). Company insiders that own Infinity Pharmaceuticals stock include Adelene Q Perkins, Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Which institutional investors are selling Infinity Pharmaceuticals stock?

INFI stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC and Clear Harbor Asset Management LLC. View Insider Buying and Selling for Infinity Pharmaceuticals.

Which institutional investors are buying Infinity Pharmaceuticals stock?

INFI stock was purchased by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Dimensional Fund Advisors LP, GSA Capital Partners LLP and Wells Fargo & Company MN. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy shares of Infinity Pharmaceuticals?

Shares of INFI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of INFI stock can currently be purchased for approximately $2.03.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $113.82 million and generates $6 million in revenue each year. The biotechnology company earns $-41,830,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. Infinity Pharmaceuticals employs 22 workers across the globe.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]

MarketBeat Community Rating for Infinity Pharmaceuticals (INFI)

Community Ranking:		2.4 out of 5 ( )
Outperform Votes:		241 (Vote Outperform)
Underperform Votes:		264 (Vote Underperform)
Total Votes:		505

MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe INFI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INFI will underperform the S&P 500 over the long term. You may vote once every thirty days.

Infinity Pharmaceuticals (NASDAQ:INFI) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

1 Wall Street analysts have issued ratings and price targets for Infinity Pharmaceuticals in the last 12 months. There are currently 1 buy rating for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	3.00	3.00	3.00	3.00
Ratings Breakdown:	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 0 Hold Rating(s) 1 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	N/A	N/A	N/A	N/A
Price Target Upside:	N/A	N/A	N/A	N/A

Infinity Pharmaceuticals (NASDAQ:INFI) Consensus Price Target History

Price Target History for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ:INFI) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
10/12/2017	Wells Fargo & Co	Upgrade	Market Perform ➝ Outperform		N/A
11/10/2016	JPMorgan Chase & Co.	Reiterated Rating	Hold		N/A
8/11/2016	Morgan Stanley	Reiterated Rating	Hold	$1.00	N/A
8/10/2016	FBR & Co	Reiterated Rating	Hold		N/A
8/9/2016	Wedbush	Reiterated Rating	Neutral	$1.25 ➝ $1.00	N/A
6/15/2016	Jefferies Group	Downgrade	Buy ➝ Hold		N/A
6/15/2016	William Blair	Downgrade	Outperform ➝ Market Perform	$20.00 ➝ $2.00	N/A
6/14/2016	Royal Bank of Canada	Downgrade	Outperform ➝ Sector Perform	$12.00 ➝ $2.00	N/A
6/14/2016	JMP Securities	Downgrade	Outperform ➝ Market Perform		N/A

(Data available from 5/27/2016 forward)

Infinity Pharmaceuticals (NASDAQ:INFI) Earnings History and Estimates Chart

Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ:INFI) Earnings Estimates

2018 EPS Consensus Estimate: ($0.91)
2019 EPS Consensus Estimate: ($0.60)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.30)	($0.30)	($0.30)
Q2 2018	1	($0.21)	($0.21)	($0.21)
Q3 2018	1	($0.21)	($0.21)	($0.21)
Q4 2018	1	($0.19)	($0.19)	($0.19)
Q1 2019	1	$0.18	$0.18	$0.18
Q2 2019	1	($0.25)	($0.25)	($0.25)
Q3 2019	1	($0.26)	($0.26)	($0.26)
Q4 2019	1	($0.27)	($0.27)	($0.27)

Infinity Pharmaceuticals (NASDAQ INFI) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/8/2018	Q1 2018	($0.1820)	($0.18)			View	N/A
3/15/2018	Q4 2017	($0.25)	($0.14)			View	Listen
11/7/2017	Q3 2017	($0.20)	($0.14)	$14.70 million	$6.00 million	View	N/A
8/3/2017	Q2 2017	($0.22)	($0.34)			View	Listen
5/9/2017	Q1 2017	($0.22)	($0.21)	$19.60 million	$0.01 million	View	Listen
3/14/2017	Q4 2016	($0.57)	($0.46)	$2.33 million		View	N/A
11/9/2016	Q316	($0.84)	($0.39)	$6.23 million		View	Listen
8/9/2016	Q216	($0.89)	$1.05	$13.91 million	$9.47 million	View	Listen
5/4/2016	Q116	($0.82)	($0.82)	$8.80 million	$9.26 million	View	Listen
2/23/2016	Q415	($0.72)	($0.80)	$18.26 million	$9.10 million	View	Listen
11/5/2015	Q315	($0.76)	$0.84	$24.85 million	$90.70 million	View	N/A
8/6/2015	Q215	($1.00)	($0.78)	$5.83 million	$4.90 million	View	N/A
5/6/2015	Q115	($1.69)	($1.91)	$5.79 million	$4.40 million	View	Listen
2/24/2015	Q414	($0.99)	($0.83)	$5.61 million	$4.36 million	View	Listen
11/6/2014	Q314	($0.87)	$2.03	$141.40 million	$160.60 million	View	Listen
8/5/2014	Q114	($0.84)	($0.78)			View	N/A
5/6/2014	Q1	($0.80)	($0.87)			View	Listen
2/25/2014	Q413	($0.87)	($0.68)			View	Listen
11/7/2013		($0.75)	($0.71)			View	N/A
8/8/2013	Q2 2013	($0.62)	($0.68)			View	Listen
5/7/2013	Q1 2013	($0.67)	($0.57)			View	N/A
3/5/2013	Q4 2012	($0.89)	($1.15)			View	N/A
11/6/2012	Q312	($0.57)	$0.52	$13.90 million		View	N/A
8/7/2012	Q2 2012	($0.38)	($0.54)			View	N/A
5/8/2012	Q1 2012	($0.37)	($0.40)			View	N/A
3/13/2012	Q4 2011	($0.42)	($0.53)			View	N/A
11/8/2011	Q3 2011	($0.40)	($0.45)			View	N/A
8/9/2011	Q2 2011	($0.36)	($0.44)			View	N/A
5/10/2011	Q1 2011	($0.36)	($0.09)			View	N/A
3/15/2011	Q4 2010	($0.39)	($0.56)			View	N/A
11/9/2010	Q3 2010	($0.76)	($0.81)			View	N/A
8/4/2010	Q2 2010	($0.32)	($0.24)			View	N/A
5/6/2010	Q1 2010	($0.34)	($0.32)			View	N/A
2/10/2010	Q4 2009	($0.42)	($0.30)			View	N/A
11/9/2009	Q3 2009	($0.44)	($0.36)			View	N/A
8/5/2009	Q2 2009	($0.52)	($0.50)			View	N/A
5/4/2009	Q1 2009	($0.08)	($0.15)			View	N/A
2/9/2009	Q4 2008	$1.01	$2.11			View	N/A
10/29/2008	Q3 2008	($0.57)	($0.63)			View	N/A
8/4/2008	Q2 2008	($0.41)	($0.57)			View	N/A
5/5/2008	Q1 2008	($0.37)	$0.02			View	N/A
2/13/2008	Q4 2007	($0.27)	($0.40)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Infinity Pharmaceuticals (NASDAQ:INFI) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 11.45%
Institutional Ownership Percentage: 50.55%

Insider Trading History for Infinity Pharmaceuticals (NASDAQ:INFI)

Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/10/2018	Value Fund L P Biotechnology	Major Shareholder	Buy	1,510,000	$1.97	$2,974,700.00
3/5/2018	Adelene Q Perkins	CEO	Sell	5,000	$2.78	$13,900.00	607,252
12/6/2017	Lawrence E Bloch	President	Buy	500,000	$1.81	$905,000.00	580,944
10/4/2017	Value Fund L P Biotechnology	Insider	Buy	1,600,046	$1.26	$2,016,057.96
3/17/2017	Michael C Venuti	Director	Sell	6,250	$3.48	$21,750.00	50,000
1/3/2017	Value Fund L P Biotechnology	Major Shareholder	Buy	4,379	$1.34	$5,867.86
12/30/2016	Value Fund L P Biotechnology	Major Shareholder	Buy	742,401	$1.34	$994,817.34
12/20/2016	Value Fund L P Biotechnology	Major Shareholder	Buy	654,921	$1.31	$857,946.51
12/13/2016	Sujay Kango	Insider	Sell	75,000	$1.28	$96,000.00	50,590
12/12/2016	Sujay Kango	Insider	Sell	25,009	$1.30	$32,511.70	50,590
12/2/2016	Value Fund L P Biotechnology	Major Shareholder	Buy	201,394	$1.19	$239,658.86
6/25/2015	Adelene Q Perkins	CEO	Sell	5,000	$10.93	$54,650.00
6/15/2015	Vito J Palombella	Insider	Sell	4,737	$10.97	$51,964.89
5/27/2015	Adelene Q Perkins	CEO	Sell	10,000	$12.81	$128,100.00
5/14/2015	Adelene Q Perkins	CEO	Sell	10,000	$12.18	$121,800.00
3/16/2015	Adelene Q Perkins	CEO	Sell	20,000	$16.00	$320,000.00
1/29/2015	Adelene Q Perkins	CEO	Sell	20,000	$14.83	$296,600.00
12/15/2014	Vito J Palombella	Insider	Sell	4,737	$16.32	$77,307.84
11/26/2014	Vito J Palombella	Insider	Sell	4,736	$15.00	$71,040.00
9/30/2014	Anthony B Evnin	Director	Sell	112,451	$13.56	$1,524,835.56
9/3/2014	Vito J Palombella	Insider	Sell	9,472	$15.39	$145,774.08
11/27/2013	Anthony B Evnin	Director	Sell	163,864	$14.82	$2,428,464.48
9/13/2013	Adelene Perkins	CEO	Sell	45,000	$20.72	$932,400.00	447,535
6/20/2013	Vito J Palombella	Insider	Sell	23,150	$18.53	$428,969.50
11/26/2012	Christopher M Lindblom	Insider	Sell	13,885	$25.73	$357,261.05
9/7/2012	Co Beacon	Major Shareholder	Buy	5,416,565	$14.50	$78,540,192.50

(Data available from 1/1/2013 forward)

Infinity Pharmaceuticals (NASDAQ INFI) News Headlines

Source:

Date	Headline
	Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify ... www.businesswire.com - May 23 at 5:35 PM
	Serametrix MDSC Assay Being Utilized By Infinity Pharmaceuticals in the First Clinical Study to Prospectively Identify Patients With High Blood Levels of MDSCs finance.yahoo.com - May 22 at 5:09 PM
	Zacks Investment Research Lowers Infinity Pharmaceuticals (INFI) to Hold www.americanbankingnews.com - May 16 at 1:35 PM
	Pancreatic Cancer Market is Determined to Cross US$ 13 Billion By 2023 www.marketwatch.com - May 14 at 5:20 PM
	Brokerages Anticipate Infinity Pharmaceuticals, Inc. (INFI) to Announce -$0.19 EPS www.americanbankingnews.com - May 11 at 11:24 AM
	William Blair Weighs in on Infinity Pharmaceuticals, Inc.'s Q2 2018 Earnings (INFI) www.americanbankingnews.com - May 11 at 9:35 AM
	Edited Transcript of INFI earnings conference call or presentation 8-May-18 8:30pm GMT finance.yahoo.com - May 11 at 8:28 AM
	Analysts Offer Predictions for Infinity Pharmaceuticals, Inc.'s Q1 2019 Earnings (INFI) www.americanbankingnews.com - May 10 at 8:42 AM
	Infinity Pharmaceuticals (INFI) Posts Earnings Results, Hits Estimates www.americanbankingnews.com - May 9 at 1:31 PM
	Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 9 at 8:19 AM
	Infinity: 1Q Earnings Snapshot finance.yahoo.com - May 9 at 8:19 AM
	Infinity Pharmaceuticals Provides Company Update and First Quarter 2018 Financial Results www.bizjournals.com - May 8 at 5:39 PM
	BRIEF-Infinity Pharmaceuticals Q1 Loss Per Share $0.18 www.reuters.com - May 8 at 5:39 PM
	Infinity Announces The Date Of Its First Quarter 2018 Financial Results Conference Call And Webcast finance.yahoo.com - May 1 at 5:18 PM
	BRIEF-Infinity Pharmaceuticals Files Prospectus Relates To Resale Of Up To 1.1 Mln Shares Of Co's Common Stock - SEC Filing www.reuters.com - May 1 at 8:26 AM
	Gamida Cell Strengthens Leadership Team with Appointments of Josh Hamermesh as Chief Business Officer and Paul ... www.businesswire.com - April 26 at 8:17 AM
	Form DEF 14A INFINITY PHARMACEUTICALS For: Jun 12 www.streetinsider.com - April 26 at 8:17 AM
	MaxCyte Appoints Dr. Claudio Dansky Ullmann as Chief Medical Officer www.prnewswire.com - April 26 at 8:17 AM
	Brokerages Expect Infinity Pharmaceuticals Inc. (INFI) to Announce -$0.18 Earnings Per Share www.americanbankingnews.com - April 23 at 11:10 PM
	Why Is Infinity Pharmaceuticals (INFI) Down 18.3% Since its Last Earnings Report? finance.yahoo.com - April 16 at 8:16 AM
	BRIEF-BVF Partners Reports 21.7 Pct Stake In Infinity Pharmaceuticals As Of April 10 www.reuters.com - April 13 at 8:19 AM
	Why Infinity Pharmaceuticals (INFI) Could Shock the Market Soon finance.yahoo.com - April 12 at 5:38 PM
	Insider Buying: Infinity Pharmaceuticals Inc. (INFI) Major Shareholder Acquires 1,510,000 Shares of Stock www.americanbankingnews.com - April 11 at 7:09 PM
	-$0.18 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter www.americanbankingnews.com - April 7 at 1:13 AM
	Zacks Investment Research Upgrades Infinity Pharmaceuticals (INFI) to "Hold" www.americanbankingnews.com - April 6 at 8:45 PM
	Are Options Traders Betting on a Big Move in Infinity Pharmaceuticals (INFI) Stock? www.zacks.com - March 28 at 8:28 AM
	Infinity Pharmaceuticals (INFI) Presents At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference - Slideshow seekingalpha.com - March 27 at 5:14 PM
	Infinity to Present at Two Upcoming Conferences finance.yahoo.com - March 26 at 5:18 PM
	Can The Uptrend Continue for Infinity Pharmaceuticals (INFI)? finance.yahoo.com - March 22 at 8:26 AM
	Infinity To Present At BioCentury's 25th Annual Future Leaders In The Biotech Industry Conference finance.yahoo.com - March 21 at 5:37 PM
	Brokerages Anticipate Infinity Pharmaceuticals Inc. (INFI) Will Announce Earnings of -$0.18 Per Share www.americanbankingnews.com - March 21 at 1:26 AM
	William Blair Comments on Infinity Pharmaceuticals Inc.'s Q1 2019 Earnings (INFI) www.americanbankingnews.com - March 19 at 5:16 AM
	Infinity (INFI) Reports Narrower-than-Expected Loss in Q4 - Nasdaq www.nasdaq.com - March 17 at 8:26 AM
	Edited Transcript of INFI earnings conference call or presentation 15-Mar-18 8:30pm GMT finance.yahoo.com - March 16 at 6:29 PM
	Infinity Pharmaceuticals (INFI) Posts Quarterly Earnings Results, Beats Estimates By $0.11 EPS www.americanbankingnews.com - March 16 at 9:44 AM
	Infinity Pharmaceuticals Provides Company Update and Reports ... - PR Newswire (press release) www.prnewswire.com - March 16 at 8:20 AM
	Infinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q4 2017 Results - Earnings Call Transcript - Seeking Alpha seekingalpha.com - March 16 at 8:20 AM
	Infinity Pharmaceuticals Provides Company Update and Reports Fourth Quarter and Full Year 2017 Financial Results finance.yahoo.com - March 15 at 6:12 PM
	Infinity Pharmaceuticals, Inc. to Host Earnings Call finance.yahoo.com - March 15 at 6:12 PM
	Infinity Pharmaceuticals Announces Additions to Board of Directors ... - PR Newswire (press release) www.prnewswire.com - March 9 at 8:20 AM
	Infinity Announces the Date of Its Fourth Quarter and Full Year 2017 Financial Results Conference Call and Webcast finance.yahoo.com - March 8 at 6:43 PM
	Infinity Pharmaceuticals Announces Additions to Board of Directors and Clinical Leadership Team and Establishes Scientific Advisory Board finance.yahoo.com - March 8 at 6:43 PM
	Infinity Pharmaceuticals Inc. (INFI) CEO Sells $13,900.00 in Stock www.americanbankingnews.com - March 7 at 7:46 PM
	Head-To-Head Survey: Immunomedics (IMMU) vs. Infinity Pharmaceuticals (INFI) www.americanbankingnews.com - March 5 at 11:36 AM
	Infinity Pharmaceuticals (INFI) to Release Quarterly Earnings on Monday www.americanbankingnews.com - March 5 at 2:16 AM
	-$0.25 EPS Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter www.americanbankingnews.com - March 3 at 9:10 PM
	Notice of Annual General Meeting Copenhagen Stock Exchange:LUN - GlobeNewswire (press release) globenewswire.com - February 19 at 8:16 AM
	Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per Share www.americanbankingnews.com - February 15 at 3:16 AM
	Mid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses Views www.nasdaq.com - February 14 at 4:05 PM
	Infinity Pharmaceuticals (INFI) Presents At BIO CEO & Investor Conference - Slideshow seekingalpha.com - February 13 at 3:44 PM

Infinity Pharmaceuticals (NASDAQ:INFI) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Infinity Pharmaceuticals (NASDAQ:INFI) Income Statement, Balance Sheet and Cash Flow Statement

Infinity Pharmaceuticals (NASDAQ INFI) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff